SWEDISH ORPHAN BIOVITRUM AB Sobi plans to publish its report for the third quarter of 2023 on 30 October 2023 at 08:00 CET.
Investors, analysts, and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session on the same day at 13:00 pm CET, 12:00 pm GMT, and 8:00 am EDT.
The presentation can be followed live hereor afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.
To participate in the conference call, please use the following dial-in details:
Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13
For other countries, please get details here
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedInand YouTube.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
To stay up to date with our development, please subscribe to our press releases.
Sign up
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Swedish Orphan Biovitrum AB published this content on 18 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 October 2023 13:03:35 UTC.
